Acute Effect of a Proprietary Botanical Blend Rich in Polyphenols on Flow-mediated Dilation in Healthy Subjects

Acute Dose-response Effect of a Proprietary Botanical Blend Rich in Polyphenols on Flow-mediated Dilation in Healthy Subjects: Randomized, Cross-over, Double-blind Clinical Study

It is well established that endothelial dysfunction is an early predictor of cardiovascular events in at-risk patients. Finding safe and effective product able to improve endothelial function is of public health interest.

Many clinical studies have shown that monomer of flavanols from cocoa significantly improved endothelial function, in particular endothelium-dependent flow-mediated dilation (ED-FMD) after a single dose. Grape is also a main source of flavanol monomers, that's why many human studies have shown significant effects of grape-derived products on endothelial function within 2 hours following a single dose intake.

The objective of this study is to assess the effect of 2 doses of a proprietary and standardised botanical blend rich in polyphenols (SBRP), on ED-FMD in fasting conditions, in comparison to a placebo, in healthy adults. This blend is made of two botanical extracts: a grape extract and a blueberry extract. In order to provide supportive evidence on the mechanisms and biological plausibility to the clinical effects of the product, appropriate biological parameters and circulating metabolites will be assayed.

Study Overview

• Status: Completed
• Conditions: Healthy
• Intervention / Treatment: Dietary supplement: Memophenol 300 mg; Dietary supplement: Memophenol 600 mg; Dietary supplement: Placebo

• Study Type: Interventional
• Enrollment (Actual): 18
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Clermont-Ferrand cedex 1, France, 63003
    • CIC Inserm 1405, University Hospital Clermont-Ferrand,

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 45 years (Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Presenting at least two of the following risks of suboptimal endothelial function (but not under prescribed drug for this reason):
• Overweight, defined by: 25 ≤ BMI < 30 kg/m2;
• Central obesity defined according to IDE criteria (2009): for European subjects, waist circumference ≥ 94 cm (with a tolerance of -10%);
• High Normal Blood pressure defined according to ESC/ESH guidelines (2013): Systolic Blood Pressure ≥ 130 and ≤ 139 mmHg or Diastolic Blood Pressure ≥ 85 and ≤ 89 mmHg;
• Considered healthy based on their self-declaration and physical examination;
• Subjects capable of and willing to comply with the protocol and to give their written informed consent.
• Subjects affiliated with a social security scheme.

Non-inclusion Criteria:

• Metabolic abnormality or major cardiovascular risk factor, such as (but not limited to):
• clinically significant arrhythmia,
• diabetes mellitus (type I or II),
• chronic kidney disease.
• Consumption of food supplement(s) currently or within the past 4 weeks before entry into the study, such as but not limited to: botanicals, vitamins, minerals, amino acids;
• Smoking > 5 cigarettes/ day and > 5 pack-years for at least 2 years;
• Use of any type of medication currently or within 2 months before entry into the study (more especially antihypertensive drug);
• Use of any narcotic drug (including cannabis) within 2 months before entry into the study detected by the self-declaration of the participant and/ or by the urine THC test ;
• Endurance sport activities > 5 h/ week;
• Self-reported alcohol intake >10 units/ week (1 unit = 1 standard glass)
• Weight change > 5% of total body weight within the 3 months before V1;
• Currently under prescribed diet regimen, whatever the reason;
• Any intolerance or allergy documented or suspected to one of the components of the study products or to the Glyceryl trinitrate (GTN);
• Any contraindication to the GTN drug:
• severe hypotension,
• obstructive cardiomyopathy,
• myocardial infarction,
• intracranial hypertension,
• sildenafil intake (occasionally or regularly). .
• Subject presenting a psychological or linguistic inability to sign the informed consent;
• Subject under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision;
• Subject participating in another biomedical study or participation in another study within the 3 months before entry into this study;
• Any regulatory reason according to national applicable regulation.

Exclusion criteria :

Volunteers whose fasting blood sample at V0 will reveal a pathological level of glycaemia (> 1,26 g/L) and/ or a dyslipidemia (example : triacylglycerol > 1,75 g/L) will be excluded.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: SBRP 300 mg; 300 mg standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.	Dietary supplement: Memophenol 300 mg; 300 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
Experimental: SBRP 600 mg; 600 mg standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.	Dietary supplement: Memophenol 600 mg; 600 mg a proprietary, standardized botanical blend rich in polyphenols (SBRP) and especially in monomers of flavanols.
Placebo Comparator: Placebo; Colored maltodextrin	Dietary supplement: Placebo; Colored maltodextrin

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in endothelium-dependent flow-mediated dilation (ED-FMD)	ED-FMD : maximal change in the diameter of the brachial artery induced by increased flow, expressed in percentage (%) of the basal diameter.	Between Baseline (Before product intake) and 2 hours after product intake

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in endothelium-independent vasodilation (EIVD)	EIVD : Baseline diameter of the brachial artery will be assessed, and the increase in diameter of the brachial artery after application of glyceryl trinitrate will be measured .	Between Baseline (Before product intake) and 2 hours after product intake
Change in diastolic blood pressure	Blood pressure will be measured 3 times separated by 3-minute intervals. The average of the 3 measurements will be calculated.	Between Baseline (Before product intake) and 2 hours after product intake
Change in systolic blood pressure	Blood pressure will be measured 3 times separated by 3-minute intervals. The average of the 3 measurements will be calculated.	Between Baseline (Before product intake) and 2 hours after product intake

Collaborators and Investigators

• Sponsor: Activ'inside
• Collaborators: CIC Inserm 1405, University Hospital Clermont-Ferrand, France
• Investigators: Principal Investigator: Gisèle Pickering, CIC Inserm 1405, University Hospital Clermont-Ferrand, France

Study record dates

Study Major Dates

• Study Start (Actual): February 1, 2021
• Primary Completion (Actual): December 11, 2023
• Study Completion (Actual): December 11, 2023

Study Registration Dates

• First Submitted: January 5, 2021
• First Submitted That Met QC Criteria: January 5, 2021
• First Posted (Actual): January 6, 2021

Study Record Updates

• Last Update Posted (Actual): February 14, 2024
• Last Update Submitted That Met QC Criteria: February 13, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Keywords: endothelial function; healthy adults; grape and blueberry extracts; flavanol monomers
• Additional Relevant MeSH Terms: Pathological Conditions, Anatomical; Dilatation, Pathologic
• Other Study ID Numbers: FMD1-AI-2020

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No